摘要
目的观察氯沙坦、螺内酯对急性心肌梗死早期基质金属蛋白酶-9(MMP-9)的影响,探讨其作用机制,为临床提供依据。方法建立大鼠心肌梗死模型,早期应用醛固酮受体拮抗剂螺内酯20 mg·d^(-1)·kg^(-1)(螺内酯组)、血管紧张素-ⅡAT_1受体拮抗剂氯沙坦10 mg·d^(-1)·kg^(-1)(氯沙坦组)进行干预,另设假手术组(Sham组)和急性心肌梗死组(AMI组),利用免疫组化的方法 ,观察各组心肌MMP-9蛋白的表达。结果与Sham组比较,AMI组MMP-9蛋白水平升高(P<0.01);与AMI组比较氯沙坦、螺内酯组平台期心肌MMP-9蛋白表达降低(P<0.01),且氯沙坦组较螺内酯组下降更明显(P<0.01)。结论氯沙坦、螺内酯有助于改善急性心肌梗死后心脏重构。
Objective To explore effects of losartan,spironolactone therapy on metalloproteinases-9（MMP- 9） during early stage after myocardial infarction in rats,and their mechanisms,thus provide evidence for clinic.Methods Established myocardial infarction model,early application of aldosterone receptor antagonist spironolactone 20 mg·d^（-1）·kg^（-1）（spironolactone group）,angiotensin-Ⅱreceptor antagonist losartan 10mg·d^（-1）·kg^（-1）（losartan group）, sham operation（Sham group） and acute myocardial infarction group（AMI group）,MMP-9 protein expression were detected by immunohistochemistry.Results Compared with Sham group,the expression of MMP-9 increased significantly in AMI group（P0.01）,compared with AMI group,the expression of MMP-9 in losartan group and spironolactone group decreased after myocardial infarction（P0.01）,and decreased more in losarton group（P0.01）. Conclusion Losartan,spironolactone could help to improve the prognosis of acute myocardial infarction.
出处
《疑难病杂志》
CAS
2010年第9期654-656,F0003,共4页
Chinese Journal of Difficult and Complicated Cases
关键词
氯沙坦
螺内酯
心肌梗死
基质金属蛋白酶-9
Losartan
Spironolactone
Myocardial infarction
Matrix metalloprotease-9
